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Background: Treating elderly non–small-cell lung cancer (NSCLC) 
patients in the salvage setting is challenging because of concerns of 
intolerance to therapy. Here we report outcomes (survival and toxic-
ity) of elderly patients on the Biomarker-Integrated Approaches of 
Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. 
Methods: Two hundred and fifty-five chemorefractory NSCLC 
patients received tumor molecular analysis, and were random-
ized to erlotinib, erlotinib-bexarotene, vandetanib, or sorafenib. 
Retrospective subgroup analyses were conducted comparing out-
comes among age groups (< 65 versus ≥ 65 years; < 70 versus ≥ 70 
years; < 75 versus ≥ 75 years), treatments, and sex. 
Results: Median age was 62 years (range, 26–84); 38% were aged 65 
years or more. No significant differences among age groups were seen 
in rates of biopsy-related pneumothorax, treatment-related death, com-
pliance, grade 3 to 4 hematologic toxicities, response rate, nor overall 
survival. However, older women aged 65 years or more had more grade 
3 to 4 nonhematologic toxicities (p = 0.05). Elderly men aged 65 years 
or more (p = 0.008) had a higher disease-control rate at 8 weeks and 
a better progression-free survival (PFS) (p = 0.0068). Elderly women 
aged 70 years or more had a trend toward higher 8-week disease-control 
rate (p = 0.06). Older men aged 65 years or more treated with vande-
tanib had a better median PFS (p = 0.03) whereas PFS of older women 
aged 70 years or more was worse (p = 0.03) compared with younger 
patients. Elderly men aged 70 years or more treated with sorafenib 
had a higher overall survival compared with younger men (p = 0.04). 
Tumor tissue biomarkers show distinct differences by sex and age. 
Conclusion: Fit elderly NSCLC patients should be considered 
for salvage targeted therapy. In this subset of patients, older men 
seem to have significant clinical benefit from certain agents. Tumor 
biomarker analysis demonstrates sex and age variations, and is 
hypothesis-generating.
Key Words: Non–small-cell lung cancer, Elderly patients, Targeted 
agents, Salvage therapy.
(J Thorac Oncol. 2012;7: 1645–1652)
Although predictive biomarkers to select patients for treat-ment with targeted agents have revolutionized non–small-
cell lung cancer (NSCLC) therapy with significant clinical 
benefits in specific patient subsets, there are currently few vali-
dated biomarkers to direct treatment decisions. Physician pref-
erence and clinical characteristics, such as patient age, often 
dictate therapy choice. However, physician concerns regard-
ing older patients’ limited tolerance for toxic therapies, espe-
cially given their frequently existing comorbidities, may lead 
to undertreatment, as indicated by studies reporting that only 
28% to 36% of patients aged 65 years or more receive frontline 
chemotherapy treatment.1,2 This finding is especially troubling 
as the median age for NSCLC diagnosis is age 71 years, and 
there is evidence that elderly patients, usually defined as aged 
65 or more, derive survival benefit when treated with systemic 
therapy in both the frontline and salvage settings.3–7
Although targeted agents are presumed to be better 
tolerated than systemic chemotherapy, few targeted-therapy 
studies focused on the elderly population. Most of the published 
data arise from unplanned subgroup analyses of elderly patients 
in large phase III trials.6,8 In the salvage setting, the majority of 
the literature involves use of epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors in the elderly population; for 
example, the BR.21 study, which tested erlotinib versus placebo, 
showed that elderly patients (aged ≥ 70 years) were more prone to 
grade 3/4 toxicity, dose reductions, and erlotinib discontinuation 
caused by toxicity.4 There are few other published data on the 
comparative efficacy and toxicity of salvage targeted agents, 
and no published tumor biomarker analysis studies focused on 
the elderly population. Thus, improving our understanding of 
elderly cancer patients’ tolerance to salvage targeted agents and 
their biomarker profiles would be advantageous in identifying 
patients from this underserved population that may benefit from 
(or be harmed by) these treatments.
We recently reported the results of the Biomarker-integrated 
Approaches of Targeted Therapy for Lung Cancer Elimination 
(BATTLE) trial,9 in which 255 pretreated NSCLC patients were 
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randomized to four separate phase II targeted therapies: erlotinib, 
erlotinib-bexarotene, vandetanib, and sorafenib. In this trial, core 
tumor biopsies were prospectively obtained for biomarker analy-
sis of 11 prespecified markers (Fig. 1). We sought to determine 
in a post hoc analysis how our elderly patients on the BATTLE I 
salvage trials compared with the nonelderly patients with respect 
to biomarker profiles, clinical outcomes, and rate of adverse 
events with the specific targeted agents.
PATIENTS AND METHODS
BATTLE enrolled chemo-refractory NSCLC patients 
at M.D. Anderson Cancer Center to receive a baseline tumor 
biopsy, molecular tumor biomarker assessments, and then 
random (using one of two algorithms) assignment to one 
of four oral therapy studies: erlotinib (150 mg daily; OSIP/
Genentech, San Francisco, CA), erlotinib (150 mg daily) 
plus bexarotene (400 mg/m2 daily; Eisai, Tokyo, Japan), 
vandetanib (300 mg daily; AstraZeneca, London, United 
Kingdom), or sorafenib (400 mg twice daily; Bayer/Onyx, 
San Francisco, CA). A treatment cycle was 4 weeks with a 
Response Evaluation Criteria in Solid Tumors radiographic 
assessment performed every 8 weeks. Adverse events (AE) 
were assessed by the National Cancer Institute-Common 
Terminology Criteria version 3.0. Eligibility criteria are 
detailed in the primary article,9 but included stage IIIB or IV 
NSCLC, pretreatment with at least one line of chemotherapy 
for metastatic disease, age 18 years or above, and Eastern 
Cooperative Oncology Group performance status 0 to 2. The 
primary endpoint of the study was the disease control rate 
(DCR) at 8 weeks, and secondary endpoints included overall 
FIGURE 1.  Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) I trial schema.
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response rate (ORR), progression-free survival (PFS), overall 
survival (OS), and toxicity. Exploratory endpoints included 
correlation of biomarkers to treatment efficacy. The 11 tumor 
specimen biomarkers that were prospectively evaluated 
included: EGFR mutations, KRAS mutations, BRAF muta-
tions, EGFR and CCND1 (Cyclin D1) gene copy numbers 
assessed by fluorescent in situ hybridization, and immunohis-
tochemistry (IHC) protein expression levels of vascular endo-
thelial growth factor (VEGF), VEGF receptor 2 (VEGFR-2), 
retinoid X receptors (RXRs) -α, -β, and -γ, and Cyclin D1. 
Classification of each biomarker as positive or negative was 
prespecified before study initiation.
The first cohort of BATTLE patients was equally ran-
domized to one of the four treatment arms, that is, without 
consideration of their biomarker profile, except for erlotinib-
refractory patients who were excluded from the erlotinib-
based arms. The biomarker profile and response data from this 
first cohort of patients was used to generate and continually 
update a Bayesian adaptive randomization algorithm using 
a posterior probability of DCR for a specific treatment; this 
algorithm was subsequently used for the second cohort of 
patients to allow more patients to be assigned to more effective 
therapies. Additional details regarding the statistical design 
can be obtained from the original article.9 The Institutional 
Review Boards of M.D. Anderson Cancer Center and the U.S. 
Department of Defense approved the study, which was moni-
tored by an independent Data and Safety Monitoring Board.
Elderly Subset Analysis
The main objective of this subgroup analysis was to ret-
rospectively evaluate the efficacy and safety/toxicity results 
among the four treatment arms of the BATTLE study for 
elderly population subgroups (defined here as ≥ age 65 years, 
≥ age 70 years, and ≥ age 75 years) compared with younger 
patients (< age 65 years, <age 70 years, < age 75 years), and 
explore differences in biomarker profiles. Comparison sub-
group analyses were conducted using Fisher’s exact test for 
age groups (<65 versus ≥ 65 years; < 70 versus ≥ 70 years; 
< 75 versus ≥ 75 years) and then between treatments and 
sex within each age category. Clinical outcomes evaluated 
included DCR, ORR, PFS, OS, and toxicity. PFS, OS, and 
response duration were estimated using the Kaplan–Meier 
method, with PFS defined as time from randomization to 
disease progression or death without progression. OS was 
defined from the randomization time to death by any cause. 
Log-rank and Cox proportional hazards model were used to 
conduct univariate and multivariate studies.
RESULTS
In the BATTLE study, the intent-to-treat population 
(n = 255) was randomized into the four treatment arms: erlotinib 
(n = 59), erlotinib-bexarotene (n =37), vandetanib (n = 54), and 
sorafenib (n = 105). Distribution of patient characteristics and 
treatment arms by age groups is seen in Table 1. The median age 
for all intent-to-treat patients was 62 years (range, 26–84) with 
62% patients aged 64 years or lesser and 38% aged 65 years or 
more. There were 244 patients evaluable for DCR at 8 weeks, and 
2562 AE were recorded among 250 patients receiving therapy.
Toxicity
AE related to the core lung biopsy procedure included 
an overall 11.5% rate of pneumothorax, with one grade 3 
event that required overnight hospitalization. There was no 
increased incidence of pneumothorax in patients aged more 
than 65, 70, or 75 years. There was also no difference in treat-
ment-related mortality between the age groups.
Overall compliance with treatment by age groups or 
by sex–age groups in almost all patients was not statistically 
significantly different, with an average of 95% compliance in 
each treatment arm. The only exception was in women aged 
70 years or more treated on the erlotinib+bexarotene arm, who 
had worse compliance (81.6% versus 99.3%, p = 0.04). Women 
aged 65 years or more (25.6% versus 10.3%, p = 0.03) and 
those aged 70 years or more (35% versus 11.3%, p = 0.0076) 
were also more likely to require dose reductions, irrespective 
of treatment arm. No other subgroups had significant dose-
reduction differences. Treatment discontinuation rates caused by 
toxicity were similar among the age groups: 14.5% for patients 
aged less than 65 years, 12.5% for those aged 65 years or more, 
14.6% for those aged 70 years or more, and 13% for those aged 
75 years or more, with higher treatment-discontinuation rates in 
the sorafenib and vandetanib treatment arms for all ages.
No differences were seen among the overall age groups 
in rate of grade 3 to 4 hematologic toxicities; however, younger 
men (< 65 years) had more grade 2 hematologic AE with 
sorafenib (60% versus 12.5%, p = 0.03). Differences were 
seen with both age and sex in the elderly patients (age ≥ 65 
years) for the nonhematologic toxicities, which were mainly 
diarrhea and any gastrointestinal complaints (anorexia, dys-
phagia, diarrhea, flatulence, nausea, vomiting, dyspepsia, and 
others). Older women aged 65 years or more had more grade 3 
to 4 nonhematologic toxicities (69.2% versus 50%, p = 0.05), 
especially in the sorafenib treatment arm (p = 0.04). In con-
trast, younger men (age < 65 years and < 70 years) had more 
grade 3 to 4 nonhematologic toxicities (51.3% versus 33.3%, 
p = 0.041; 50.5% versus 24.2%, p = 0.0085). Of interest, 
any patient, regardless of age, who experienced any grade of 
hypertension (HTN) or skin rash had an improved DCR (p = 
0.02; p = 0.0001), PFS (p = 0.02; p < 0.001) and OS (p = 0.09; 
p < 0.0001). Almost all the patients who experienced HTN 
were treated with either vandetanib or sorafenib. Although 
the grade of HTN was not associated with DCR, PFS, or OS, 
there was a trend toward improved PFS (p = 0.07) and OS 
(p = 0.06) with a higher grade of skin rash.
Response and Disease Control
There was no difference in ORR between any age group 
or sex. However, patients aged 65 years or more had a higher 
DCR than younger patients (55.4% versus 40%, respectively; 
p = 0.02), especially in men (62% versus 38%, p = 0.008). The 
8-week DCR was significantly higher in men aged 70 years 
or more (64% versus 43%, p = 0.04) and men aged 75 years 
or more (75% versus 45%, p = 0.07) compared with younger 
men. All patients aged 70 years or more had a higher DCR 
than younger patients (64% versus 41%; p = 0.004), especially 
women (63% versus 39%, p = 0.056). The only treatment that 
showed a DCR difference by age or sex was the erlotinib 
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monotherapy arm, in which treated men aged 70 years or more 
had a higher DCR than younger men did (67% versus 26%,  
p = 0.05).
Survival Outcomes
There was no difference in PFS between any of the 
overall age groups; however, similar to the DCR findings, 
sex–age subgroup analysis demonstrated that men aged 
65 years or more had a better median PFS compared with 
younger men (2.8 months versus 1.8 months, p = 0.0068) 
(Fig. 2A). A trend for this median PFS benefit was also seen 
in men aged 70 years or more (2.8 versus 1.84 months, 
p = 0.09). When assessing specific treatments, elderly men 
aged 65 years or more treated with vandetanib had a better 
median PFS (3.7 months versus 1.8 months, p = 0.03) than 
younger men did (Fig. 2B). The opposite effect was seen 
in elderly women aged 70 years or more, who had a worse 
median PFS with vandetanib (1.1 months versus 1.8 months, 
p = 0.03; Fig. 2C) compared with younger women. When 
comparing sex in the treatment arms, younger women aged 
less than 65 years treated with erlotinib-bexarotene had a 
better PFS than younger men aged less than 65 years did 
(p = 0.01), whereas older men aged 65 years or more had a 
better PFS than older women aged 65 years or more in the 
vandetanib arm did (p = 0.06).
There were no statistically significant differences in OS 
among any of the age groups; however, when factoring in sex 
to the age categories, elderly women aged 70 years or more 
(6.5 months versus 9.03 months, p = 0.57) and 75 years or 
more (6.28 months versus 9.0, p = 0.43) had a worse median 
OS than younger women did. Given that more elderly women 
required dose reductions, a subgroup analysis of only women 
who received full-dose treatment confirmed a trend for a 
shorter median OS in the elderly women, but did not reach sta-
tistical significance. Older men trended in the opposite direc-
tion, with those aged 70 years or more (11.3 months versus 
7.6 months, p = 0.31) having an improved median OS. When 
accounting for the separate treatments by sex and age, men 
aged 70 years or more had a significantly improved median 
OS compared with younger men with sorafenib did (15.0 
months versus 6.4 months, p  = 0.04; Fig. 3).





Age 65 Yrs Cutoff Age 70 Yrs Cutoff Age 75 Cutoff Yrs
Age < 65 Yrs 
N = 159
Age > 65 Yrs 
N = 96
Age < 70 Yrs 
N = 200
Age > 70 Yrs 
N = 55
Age < 75 Yrs 
N = 232
Age > 75 Yrs 
N = 23
Sex
 Female 118 (46%) 78 (49%) 40 (42%) 97 (49%) 21 (38%) 107 (46%) 11 (48%)
 Male 137 (54%) 81 (51%) 56 (58%) 103 (51%) 34 (62%) 125 (54%) 12 (52%)
Histology
 Adenocarcinoma 160 (63%) 101 (64%) 59 (61%) 128 (64%) 32 (58%) 145 (63%) 15 (65%)
 Squamous 46 (18%) 32 (20%) 17 (18%) 34 (17%) 11 (20%) 42 (18%) 4 (17%)
 Other 49 (19%) 26 (16%) 20 (21%) 38 (19%) 12 (22%) 45 (19%) 4 (17%)
Erlotinib resistance 116 (45%) 71 (45%) 45 (47%) 90 (45%) 26 (47%) 106 (46%) 10 (44%)
ECOG PS
 0 22 (9%) 16 (10%) 6 (6%) 18 (9%) 4 (7%) 22 (9%) 0 (0%)
 1 197 (77%) 119 (75%) 78 (81%) 153 (77%) 44 (80%) 178 (77%) 19 (83%)
 2 36 (14%) 24 (15%) 12 (13%) 29 (15%) 7 (13%) 32 (14%) 4 (17%)
Smoking
 Current 23 (9%) 17 (11%) 6 (6%) 22 (11%) 1 (2%) 23 (10%) 0 (0%)
 Former 177 (69%) 98 (62%) 79 (82%) 129 (65%) 48 (87%) 155 (67%) 22 (96%)
 Never 55 (22%) 44 (28%) 11 (12%) 49 (24%) 6 (11%) 54 (23%) 1 (4%)
Treatment arm
 Erlotinib 59 39 (25%) 20 (21%) 47 (24%) 12 (22%) 54 (23%) 5 (22%)
 Erlotinib-bexarotene 37 24 (15%) 13 (13%) 45 (22%) 9 (16%) 50 (22%) 6 (26%)
 Vandetanib 54 31 (19%) 23 (24%) 28 (14%) 9 (16%) 31 (13%) 4 (17%)
 Sorafenib 105 65 (41%) 40 (42%) 80 (40%) 25 (45%) 97 (42%) 8 (35%)
Smoking pack-years 
by treatment arm
 Erlotinib 36.5 30.4 45 31.2 51.5 36 52.0
 Erlotinib-bexarotene 35.4 37.0 34.6 28.6 33.8 30 25.9
 Vandetanib 31.0 28.5 46.5 37 48.0 37 32.0
 Sorafenib 30.0 30.0 35.0 30 35.0 30 38.0
Percentages are based on respective age categories.
ECOG PS, Eastern Cooperative Oncology Group performance status.
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Biomarker Analysis by Age Groups and Sex
Tables 2 and 3 detail the incidence of discrete and con-
tinuous value biomarkers within the respective patient popu-
lations by age and sex. There was no statistically significant 
difference in biomarker expression between patients aged less 
than 65 years versus those aged 65 years or more; however, 
patients aged 70 years or more had less EGFR high-polysomy 
(p = 0.05) and lower IHC expression of nucleic RXRα (p = 
0.046). In the sex subgroup analyses, women were more likely 
than men to have an EGFR mutation (9.8% versus5.6%, p = 
0.02) and EGFR gene amplification (9.9% versus 6.1%, p = 
0.04), whereas more men had BRAF mutations (although small 
numbers, 4 men versus 1 woman, p = 0.4) and KRAS muta-
tions (23 men versus 19 women, p = 0.96). Younger women 
aged less than 65 years were more likely to have EGFR-high 
polysomy (p = 0.04), whereas older women aged 75 years or 
more trended toward less Cyclin D1 amplification (p = 0.06). 
Older men aged 65 years or more had more IHC expression of 
membrane RXRβ (p = 0.02), more Cyclin D1 amplification (p 
= 0.01), and a higher incidence of tumor KRAS mutations (p 
= 0.07). Men aged 70 years or more and those aged 75 years 
or more had less IHC expression of both nucleic RXRα (p = 
0.09, p = 0.04) and Cyclin D1 (p = 0.09, p = 0.04). Men aged 
75 years or more also had less IHC expression of cytoplasmic 
RXRγ (p = 0.04).
DISCUSSION
Our results from this retrospective subgroup analysis 
indicate that elderly patients should not be excluded from 
biopsy-driven clinical trials or additional novel therapies in 
the salvage setting on the basis of age alone. Elderly BATTLE 
patients (i.e., > 65 years of age) with advanced, chemo-
refractory NSCLC treated with these novel targeted therapies 
were shown to have comparable clinical outcomes to those 
of younger patients. The survival benefit for elderly BATTLE 
patients is also consistent with that of elderly NSCLC patients 
using salvage EGFR tyrosine kinase agents,4,10–12 as shown in 
other studies including BR.21.4
Of importance, the survival benefit for elderly patients 
in BATTLE was not associated with significantly higher rates 
of high-grade toxicity or AE. Elderly patients did experience 
more nonhematologic toxicities, primarily diarrhea and gas-
trointestinal complaints, but they were able to undergo diag-
nostic core needle biopsies and subsequent targeted therapy 




aged 65 years and more compared with younger men. 
B, Superior PFS in male patients aged 65 years and more 
compared with younger men who received vandetanib. C, 
Reports inferior PFS in women aged 70 years and more who 
were treated with vandetanib. PFS, progression-free survival; 
HR, hazards ratio; CI, confidence interval.
FIGURE 3. Men age 70 years and older treated with 
sorafenib have a superior overall survival. HR, hazards ratio; 
CI, confidence interval.
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treatment-related mortality, and without differences in rates 
of grade 3 to 4 hematologic toxicities. In addition, treatment 
toxicity discontinuation rates in our elderly population com-
pared favorably with that of all patients in other targeted ther-
apy trials,4,10–12 including the 19% treatment discontinuation 
rate for toxicities of grade 3 or more and 12% discontinua-
tion rate reported in a phase II trial of erlotinib in unselected 
chemo-naive NSCLC elderly patients (≥ 70 years).13 Unlike 
the BR.21 trial,4 our elderly patients (aged ≥ 65, age ≥ 70, and 
age ≥ 75 years) had a similar rate of treatment discontinuation 
to that of the younger patients. Also, interestingly, as reported 
in our study and others,4,10–12 dose reductions of small mol-
ecule tyrosine kinase inhibitors do not seem to impact survival 
outcomes in the elderly population, in contrast to the worse 
survival outcomes observed in elderly patients in chemother-
apy trials, who receive lower dose intensities.14
The clinical outcome results of our sex- and treatment-
specific analyses were surprising, with elderly men having 
both improved DCR and PFS compared with younger men. 
In particular, older men benefitted from sorafenib, and a 
positive association between EGFR wild-type and KRAS 
mutation phenotypes, and sorafenib benefit has previously 
been reported by this group and others.15,16 It was also unusual 
that elderly women had worse PFS with vandetanib treatment 
but no difference in OS, in contrast to prior vandetanib-based 
trials17,18 that reported improved clinical outcomes in women 
of all ages. This finding could not be explained by worse 
compliance or dose-reduction issues, as only two women 
(aged 51 and 67 years) had dose reductions on the vandetanib 
arm. In an additional analysis, we evaluated the subgroup of 
women who received full doses of their treatments and found 
no statistically significant associations between any age group 
and clinical outcome.
Divergence in sex/age outcomes by targeted therapy 
may be at least partially explained by biomarker profiles, as we 
have shown that the tumor biomarker profiles differed by age 
and sex. In this study, younger women (< 65 years) were more 
likely to have EGFR mutations and EGFR high-polysomy 
whereas elderly men had a trend toward more KRAS mutations, 
consistent with the literature.19–21 Also, all four of our BRAF-
mutated patients were former smokers, supporting a prior char-
acterization report.22 We also observed significant differences 
in nuclear RXRα expression, with lower expression in patients 
aged 70 years or more, regardless of sex. Men aged 65 or more 
had more Cyclin D1 amplification, whereas older women had 
less Cyclin D1 amplification. Men aged 75 years or more had 
the most distinct biomarker profile, with less IHC expression 
of nuclear RXRα, cytoplasmic RXRγ, and Cyclin D1.
Cyclin D1 amplification and protein overexpression are 
reported to occur in a significant percentage of NSCLCs,23,24 
with dysregulation of Cyclin D1 playing a pivotal role in the 
development of lung carcinogenesis.25 However, the literature 
remains controversial, with some studies reporting loss of Cyclin 
D1 expression associated with a worse prognosis26,27 whereas 
others25,28,29 correlate high IHC Cyclin D1 expression with 
worse OS. Studies in nonpolyposis colorectal cancer indicate 
TABLE 2.  Percentages of the Incidence of Discrete Biomarkers in the Respective Patient Populations















 < 65 vs. > 65 yrs 10.7% vs. 4.7% 12.3% vs. 3.8% 19.7% vs. 8.5% 11.2% vs. 8.4% 0.9% vs. 1.4% 5.7% vs. 7.1%
p = 0.59 p = 0.14 p = 0.41 p = 0.20 p = 0.34 p = 0.01
 < 70 vs. > 70 yrs 13.0% vs. 2.3% 14.6% vs. 1.4% 25.4% vs. 2.8% 15.8% vs. 3.7% 1.4% vs. 0.9% 10.4% vs. 2.4%
p = 0.58 p = 0.15 p = 0.05 p = 0.93 p = 0.23 p = 0.99
 < 75 vs. > 75 yrs 14.0% vs. 1.4% 15.1% vs. 0.9% 26.8% vs. 1.4% 18.1% vs. 1.4% 2.3% vs. 0.0% 11.3% vs. 1.4%
p = 0.74 p = 0.74 p = 0.41 p = 1.00 p = 1.00 p = 0.71
Female
 < 65 vs. > 65 yrs 16.3% vs. 5.1% 16.5% vs. 5.2% 15.5% vs. 5.1% 13.3% vs. 6.1% 0.0% vs. 1.0% 7.2% vs. 5.2%
p = 0.33 p = 0.31 p = 0.03 p = 0.91 p = 0.33 p = 0.49
 < 70 vs. > 70 yrs 19.4% vs. 2.0% 20.6% vs. 1.0% 28.6% vs. 2.0% 18.4% vs. 1.0% 1.0% vs. 0.0% 9.3% vs. 3.1%
p = 0.51 p = 0.18 p = 0.14 p = 0.19 p = 1.00 p = 0.41
 < 75 vs. > 75 yrs 19.4% vs. 2.0% 21.7% vs. 0.0% 29.6% vs. 1.0% 19.4% vs. 0.0% 1.0% vs. 0.0% 9.3% vs. 3.1%
p = 0.68 p = 0.19 p = 0.43 p = 0.35 p = 1.00 p = 0.06
Male
 < 65 vs. > 65 yrs 6.0% vs. 4.3% 8.7% vs. 2.6% 14.8% vs. 11.3% 9.4% vs. 10.3% 1.7% vs. 1.7% 4.4% vs. 8.7%
p = 0.66 p = 0.37 p = 0.31 p = 0.07 p = 0.62 p = 0.007
 < 70 vs. > 70 yrs 7.7% vs. 2.6% 9.6% vs. 1.7% 22.6% vs. 3.5% 13.7% vs. 6.0% 1.7% vs. 1.7% 11.3% vs. 1.7%
p = 0.71 p = 1.00 p = 0.43 p = 0.19 p = 0.19 p = 0.73
 < 75 vs. > 75 yrs 9.4% vs. 0.9% 9.6% vs. 1.7% 24.4% vs. 1.7% 17.1% vs. 2.6% 3.4% vs. 0.0% 13.0% vs. 0.0%
p = 1.00 p = 0.31 p = 1.00 p = 0.41 p = 1.00 p = 0.36
Highlighted sections indicate statistically significant differences.
1651Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 7, Number 11, November 2012 Outcomes of Elderly Patients on BATTLE Trial
that a particular Cyclin D1 polymorphism leads to earlier onset 
of cancer by a decade.30 Given these data, it is possible that 
development of NSCLC in older or elderly patients occurs via 
different signaling pathways than those in younger patients, 
and this discrepancy may require additional subset analyses in 
studies testing the prognostic value of novel biomarkers.
To our knowledge, this is the first report on the compara-
tive use of different salvage targeted therapies in the elderly 
patient population with baseline biomarker results. This anal-
ysis is limited by its retrospective nature, small numbers in 
many of the subsets, and lack of a formal quality of life analy-
sis. The limitations of the biomarker analyses include lack of 
tumor heterogeneity assessments and comparisons to chemo-
naive or postprogression tumor tissue to evaluate clonal evolu-
tion over the course of treatment. In addition, there is currently 
limited therapeutic applicability for many of these biomark-
ers. Finally, the OS results may be impacted by the known fact 
that elderly patients are routinely treated less aggressively than 
younger patients are and are likely to have fewer lines of sal-
vage therapy. This must be weighed against the potential inher-
ent bias toward enrolling more physically fit elderly patients on 
the BATTLE trial, who were motivated, physically fit to travel, 
and able to adhere to the rigorous clinical trial schedule.
Nevertheless, it can be concluded from our report that elderly 
NSCLC patients with reasonable performance status are able to 
tolerate biomarker-based, salvage targeted therapy clinical trials, 
and demonstrate similar clinical outcomes to younger patients 
with reasonable compliance rates. Our tumor tissue biomarker 
analysis show distinctive profiles by sex and age, and these data 
may be considered hypothesis-generating to shape the develop-
ment of future clinical studies in this underserved population.
REFERENCES
 1. Surveillance EaERSP: SEER cancer statistics review 1975–2007; avai-
lable at: http://seer.cancer.gov. Accessed November 2011.
 2. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line 
chemotherapy use among elderly patients with advanced non-small cell 
lung cancer in the United States. Lung Cancer 2009;63:264–270.
 3. Quoix E, Zalcman G, Oster JP, et al.; Intergroupe Francophone de 
Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet che-
motherapy compared with monotherapy in elderly patients with advanced 
non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 
2011;378:1079–1088.
 4. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib 
for advanced non-small-cell lung cancer in the elderly: an analysis of the 
National Cancer Institute of Canada Clinical Trials Group Study BR.21.  
J Clin Oncol 2008;26:2350–2357.
 5. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine 
as first-line treatment in elderly patients with advanced non-small cell 
lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 
2001;6 Suppl 1:4–7.
 6. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and safety of bevaci-
zumab-based therapy in elderly patients with advanced or recurrent non-
squamous non-small cell lung cancer in the phase III BO17704 study 
(AVAiL). J Thorac Oncol 2010;5:1970–1976.
TABLE 3.  Percentages of the Incidence of Expression of Summary Marker Groups and Immunohistochemistry Biomarkers in 










 < 65 vs. > 65 yrs 29.9% vs. 12.2% 12.1% vs. 8.8% 58.6% vs. 32.1% 57.5% vs. 29.9%
p = 0.17 p = 0.22 p = 0.35 p = 0.77
 < 70 vs. > 70 yrs 36.9% vs. 5.1% 16.7% vs. 4.2% 74.4% vs. 16.3% 73.4% vs. 14.0%
p = 0.05 p = 0.79 p = 0.44 p = 0.009
 < 75 vs. > 75 39.3% v 2.8% 19.5% vs. 1.4% 83.7% vs. 7.0% 81.3% vs. 6.1%
p = 0.43 p = 0.77 p = 0.23 p = 0.04
Female
 < 65 vs. > 65 yrs 41.8% vs. 10.2% 13.3% vs. 6.1% 60.2% vs. 30.6% 57.7% vs. 28.9%
p = 0.004 p = 0.91 p = 0.71 p = 1.00
 < 70 vs. > 70 yrs 48.0% vs. 4.1% 18.4% vs. 1.0% 76.5% vs. 14.3% 74.2% vs. 12.4%
p = 0.03 p = 0.19 p = 0.64 p = 0.22
 < 75 vs. > 75 yrs 49.0% vs. 3.1% 19.4% vs. 0.0% 83.7% vs. 7.1% 79.4% vs. 7.2%
p = 0.47 p = 0.35 p = 0.55 p = 1.00
Male
 < 65 vs. > 65 yrs 19.8% vs. 13.8% 11.1% vs. 11.1% 57.3% vs. 33.3% 57.3% vs. 30.8%
p = 0.36 p = 0.09 p = 0.74 p = 0.56
 < 70 vs. > 70 yrs 27.6% vs. 6.0% 15.4% vs. 6.8% 72.7% vs. 18.0% 72.7% vs. 15.4%
p = 0.72 p = 0.14 p = 0.69 p = 0.03
 < 75 vs. > 75 yrs 31.0% vs. 2.6% 19.7% vs. 2.6% 83.8% vs. 6.8% 82.9% vs. 5.1%
p = 1.00 p = 0.69 p = 0.24 p = 0.02
EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v-Raf murine sarcoma viral oncogene homolog B1. Bold  
sections indicate statistically significant differences.
aDefinitions of positive summary marker groups and immunohistochemistry biomarker results were previously defined in a prior publication.9
RXR, retinoid X receptors.
1652 Copyright © 2012 by the International Association for the Study of Lung Cancer
Taso et al. Journal of Thoracic Oncology  •  Volume 7, Number 11, November 2012
 7. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from sec-
ond-line cytotoxic chemotherapy: a subset analysis of a randomized 
phase III trial of pemetrexed compared with docetaxel in patients with 
previously treated advanced non-small-cell lung cancer. J Clin Oncol 
2006;24:4405–4411.
 8. Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative 
Oncology Group. Outcomes for elderly, advanced-stage non small-cell 
lung cancer patients treated with bevacizumab in combination with car-
boplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group 
Trial 4599. J Clin Oncol 2008;26:60–65.
 9. Kim ES, Herbst RS, Wistuba I, et al. The BATTLE trial: personalizing 
therapy for lung cancer. Cancer Discov 2011;1:44–53.
 10. Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit 
patients affected by advanced non-small-cell lung cancer. Br J Cancer 
2003;89:1827–1829.
 11. Hotta K, Ueoka H, Kiura K, et al. Safety and efficacy of gefi-
tinib treatment in elderly patients with non-small-cell lung cancer: 
Okayama Lung Cancer Study Group experience. Acta Oncol 2005;44: 
717–722.
 12. Wu CH, Fan WC, Chen YM, et al. Second-line therapy for elderly patients 
with non-small cell lung cancer who failed previous chemotherapy is as 
effective as for younger patients. J Thorac Oncol 2010;5:376–379.
 13. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial 
of chemotherapy-naive patients > or = 70 years of age treated with 
erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 
25:760–766.
 14. Luciani A, Bertuzzi C, Ascione G, et al. Dose intensity correlate with 
survival in elderly patients treated with chemotherapy for advanced non-
small cell lung cancer. Lung Cancer 2009;66:94–96.
 15. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van 
Suylen RJ, Postmus PE. Sorafenib in patients with advanced non-small 
cell lung cancer that harbor K-ras mutations: a brief report. J Thorac 
Oncol 2010;5:719–720.
 16. Herbst RS, BlumenscheinG, Kim E, et al. Sorafenib Treatment Efficacy 
and Kras Biomarker Status in the Biomarker-Integrated Approaches of 
Targeted Therapy For Lung Cancer Elimination (Battle) Trial. Chicago, 
IL: Proc of the American Society of Clinical Oncology, 2010.
 17. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-con-
trolled phase II study of vandetanib plus docetaxel in previously treated 
non small-cell lung cancer. J Clin Oncol 2007;25:4270–4277.
 18. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of 
vandetanib alone or with paclitaxel and carboplatin as first-line treatment 
for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407–5415.
 19. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of 
the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 
2006;1:231–239.
 20. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological 
predictors of EGFR/KRAS mutational status in primary lung adenocar-
cinomas. Mod Pathol 2010;23:159–168.
 21. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implica-
tions of EGFR and KRAS mutations in resected lung adenocarcinoma. 
J Thorac Oncol 2008;3:111–116.
 22. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients 
with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 
2011;29:2046–2051.
 23. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin 
D1 in non-small cell lung cancer: a key driver of malignant transforma-
tion. Lung Cancer 2007;55:1–14.
 24. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of 
CCND1 (cyclin D1) overexpression in primary resected non-small-cell 
lung cancer. Br J Cancer 1996;73:294–300.
 25. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 overexpression in 
bronchial epithelia of patients with lung cancer is associated with smok-
ing and predicts survival. J Clin Oncol 2003;21:2085–2093.
 26. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin 
D1 and retinoblastoma expression in combination with p53 abnormali-
ties in primary, resected non-small cell lung cancers. Clin Cancer Res 
1997;3:1051–1058.
 27. Khoury T, Alrawi S, Ramnath N, et al. Eukaryotic initiation factor-4E and 
cyclin D1 expression associated with patient survival in lung cancer. Clin 
Lung Cancer 2009;10:58–66.
 28. Buch S, Zhu B, Davis AG, et al. Association of polymorphisms in the 
cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-
digestive tract. Mol Carcinog 2005;42:222–228.
 29. Zhu J, Yu L, Zhan P, Song Y, Wang Q. The relationships between cyclin 
D1 expression and prognosis of non-small cell lung cancer. Zhongguo Fei 
Ai Za Zhi 2010;13:803–808.
 30. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects 
of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis 
colorectal cancer. Cancer Res 2000;60:249–252.
